REGENCY CENTERS CORP

Regency Centers reported strong Q3 2026 results, raising its 2026 same-property NOI growth guidance to 4.25% or higher and increasing its dividend by 6%, driven by record 97% occupancy and robust rent spreads. However, the company's early 2027 outlook projects a deceleration to mid-3% NOI growth, influenced by moderating occupancy gains, normalized bad debt, and high expense recovery rates. Additionally, refinancing maturing debt is expected to reduce long-term earnings growth by 150-200 basis points, leading analysts to press management on future growth drivers and capital allocation.

Regeneron Pharmaceuticals reported strong third-quarter 2026 results with US$5.1 billion in revenue and US$1.95 billion in net income, exceeding expectations. The company also affirmed its quarterly dividend and continued share buybacks, while expanding its BARDA agreement for Ebola treatment and presenting positive data for Libtayo in skin cancer. These results reinforce Regeneron's earnings engine, with a focus on late-stage pipeline execution and competition in eye care, and analysts anticipate continued revenue and earnings growth through 2029.